Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer?

References

• Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(6 Suppl 1):4–34.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–5; discussion 75–7.
   PubMed Web of Science ®Google Scholar
• Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315–30.
   PubMed Web of Science ®Google Scholar
• Gudjonsson S, Isfoss BL, Hansson K, Domanski AM, Warenholt J, Soller W, The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2008;54:402–8.
   PubMed Web of Science ®Google Scholar
• Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844–7.
   PubMed Web of Science ®Google Scholar
• Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients. Clin Cancer Res 2006;12:1175–83.
   PubMed Web of Science ®Google Scholar
• Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE. Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004;10:3069–75.
   PubMed Web of Science ®Google Scholar
• Hartmann A. Tissue microarray studies in bladder cancer. Scand J Urol Nephrol 2008:42(Suppl);141–6.
   Google Scholar
• Wild PJ, Kunz-Schughart LA, Stoehr R, Burger M, Blaszyk H, Simon R, High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer. Int J Oncol 2005;27:385–91.
   PubMed Web of Science ®Google Scholar
• Gomez-Roman JJ, Saenz P, Molina M, Cuevas Gonzalez J, Escuredo K, Santa Cruz S, Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 2005;11:459–65.
   PubMed Web of Science ®Google Scholar
• Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128–36.
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Fischer G, Alvarez V Jr, Ahmed A, Herrmann FR. Predicting outcome in minimally invasive (T1a and T1b) urothelial bladder carcinoma using a panel of biomarkers: a high throughput tissue microarray analysis. BJU Int 2007;100:1182–7.
   PubMed Web of Science ®Google Scholar
• Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007–13.
   PubMed Web of Science ®Google Scholar
• Lavezzi AM, Biondo B, Cazzullo A, Giordano F, Pallotti F, Turconi P, The role of different biomarkers (DNA, PCNA, apoptosis and karyotype) in prognostic evaluation of superficial transitional cell bladder carcinoma. Anticancer Res 2001;21:1279–84.
   PubMed Web of Science ®Google Scholar
• Clairotte A, Lascombe I, Fauconnet S, Mauny F, Felix S, Algros MP, Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 2006;125:119–26.
   PubMed Web of Science ®Google Scholar
• Liukkonen T, Rajala P, Raitanen M, Rintala E, Kaasinen E, Lipponen P. Prognostic value of MIB-1 score, p53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/T1) bladder cancer: a prospective comparative study. The Finnbladder Group. Eur Urol 1999;36:393–400.
   PubMed Web of Science ®Google Scholar
• Kiyoshima K, Oda Y, Kinukawa N, Naito S, Tsuneyoshi M. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor and human epidermal growth factor receptor 2. Hum Pathol 2005;36:522–30.
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A, Herrmann FR. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006;32:231–7.
   PubMed Web of Science ®Google Scholar
• Rao J, Seligson D, Visapaa H, Horvath S, Eeva M, Michel K, Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer 2002;95:1247–57.
   PubMed Web of Science ®Google Scholar
• Vardar E, Gunlusoy B, Minareci S, Postaci H, Ayder AR. Evaluation of p53 nuclear accumulation in low- and high-grade (WHO/ISUP classification) transitional papillary carcinomas of the bladder for tumor recurrence and progression. Urol Int 2006;77:27–33.
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Fischer G, Beck A, Cheney RT, Herrmann FR. Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 2006;32:439–44.
   PubMed Web of Science ®Google Scholar
• Popov Z, Gil-Diez de Medina S, Lefrere-Belda MA, Hoznek A, Bastuji-Garin S, Abbou CC, Low E-cadherin expression in bladder cancer at the transcriptional and protein level provides prognostic information. Br J Cancer 2000;83:209–14.
   PubMed Web of Science ®Google Scholar
• Imao T, Koshida K, Endo Y, Uchibayashi T, Sasaki T, Namiki M. Dominant role of E-cadherin in the progression of bladder cancer. J Urol 1999;161:692–8.
   PubMed Web of Science ®Google Scholar
• Brunner A, Verdorfer I, Prelog M, Mayerl C, Mikuz G, Tzankov A. Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers. Pathobiology 2008;75:25–33.
   PubMed Web of Science ®Google Scholar
• van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol 2010;58:433–41.
   PubMed Web of Science ®Google Scholar
• Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994;69:1120–5.
   PubMed Web of Science ®Google Scholar
• Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990;65:1619–25.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Dunn R, Strawderman M, Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 2002;26:312–9.
   PubMed Web of Science ®Google Scholar
• Sauter G, Simon R, Hillan K. Tissue microarrays in drug discovery. Nat Rev Drug Discov 2003;2:962–72.
   PubMed Web of Science ®Google Scholar
• Schultz IJ, Wester K, Straatman H, Kiemeney LA, Babjuk M, Mares J, Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol 2007;51:416–22.
   PubMed Web of Science ®Google Scholar
• Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A, Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25:2685–96.
   PubMed Web of Science ®Google Scholar
• Liedberg F, Anderson H, Chebil G, Gudjonsson S, Hoglund M, Lindgren D, Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 2008;26:17–24.
   PubMed Web of Science ®Google Scholar